𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer

✍ Scribed by Stacey A. Missmer; Christopher A. Haiman; David J. Hunter; Walter C. Willett; Graham A. Colditz; Frank E. Speizer; Michael N. Pollak; Susan E. Hankinson

Publisher
John Wiley and Sons
Year
2002
Tongue
French
Weight
90 KB
Volume
100
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Insulin‐like growth factor‐1 (IGF‐I), a potent mitogen, is hypothesized to influence breast cancer risk. In 3 previous studies, a polymorphism in the IGF‐1 gene (sequence repeat length) was associated with plasma IGF‐I level. We evaluated prospectively the relationships among a (CA)~n~ repeat polymorphism in the IGF‐1 gene, IGF‐I level and breast cancer risk in a nested case‐control study conducted within the Nurses' Health Study. Blood samples were collected in 1989–1990; up to June 1994, we identified 463 cases of breast cancer. One to 2 controls were selected per case, matched by age, menopausal status, postmenopausal hormone use, month and time of day of blood collection and fasting status, for a total of 622 controls. Although no significant trend was observed, plasma IGF‐I levels were significantly lower among controls, with no copy of the 19 allele, compared with those homozygous for the 19 (CA)~n~ repeat length (146 and 173 ng/ml, respectively; p‐value for pairwise mean comparison = 0.005). In conditional logistic regression, controlling for established breast cancer risk factors, we observed no significant association between (CA)~n~ repeat length genotype and risk of breast cancer [compared with repeat genotype 19/19—18/19 genotype relative risk (RR) = 0.96, 95% confidence interval (CI) = 0.56–1.64; 18/20 genotype RR = 0.92, 95% CI = 0.39–2.19; 19/20 genotype RR = 1.16, 95% CI = 0.82–1.64; 19/21 genotype RR = 0.69, 95% CI = 0.42–1.14; 20/20 genotype RR = 0.55, 95% CI = 0.28–1.10; 20/21 genotype RR = 0.72, 95% CI = 0.29–1.79]. Results did not vary substantially when evaluated according to menopausal status, tumor receptor status or category of other breast cancer risk factors. Although a modest association cannot be excluded, our data do not support an important relation between this IGF‐1 gene polymorphism and breast cancer risk. © 2002 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Insulin-like growth factor-I gene polymo
Insulin-like growth factor-I gene polymorphism and breast cancer risk in Chinese women
✍ Wanqing Wen; Yu-Tang Gao; Xiao-Ou Shu; Herbert Yu; Qiuyin Cai; Jeffrey R. Smith; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 86 KB 👁 1 views

## Abstract The evidence that high circulating levels of insulin‐like growth factor‐I (IGF‐I) are associated with an increased risk of breast cancer among premenopausal women lends credence to the hypothesis that genetic polymorphisms in the __IGF‐I__ gene may be involved in the disease. A populati

Free insulin-like growth factor-I and br
Free insulin-like growth factor-I and breast cancer risk
✍ Benjamin D.L. Li; M. Javad Khosravi; Hans J. Berkel; Anastasia Diamandi; Mark A. 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 56 KB 👁 2 views

Insulin-like growth factor-I (IGF-I) has mitogenic and antiapoptotic effects on breast cancer cells. Epidemiologic studies have shown that high plasma levels of IGF-I and low levels of IGF binding protein (BP)-3 are associated with increased risk of breast cancer in premenopausal women. The actions

Serum insulin-like growth factor-I, insu
Serum insulin-like growth factor-I, insulin-like growth factor binding protein-3, and the risk of pancreatic cancer death
✍ Yingsong Lin; Akiko Tamakoshi; Shogo Kikuchi; Kiyoko Yagyu; Yuki Obata; Teruo Is 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 75 KB 👁 1 views

## Abstract Recent epidemiological studies have shown that high serum levels of insulin‐like growth factor‐I (IGF‐I) are associated with an increased risk of lung, colon, breast and prostate cancer. Since very few studies have addressed the role of serum levels of IGF‐I in the development of pancre

Premenopausal levels of circulating insu
Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer
✍ Dana E. Rollison; Craig J. Newschaffer; Yuzhen Tao; Michael Pollak; Kathy J. Hel 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 94 KB 👁 1 views

## Abstract Increased levels of insulin‐like growth factor I (IGF‐I) may directly stimulate breast cell proliferation and promote growth and survival of transformed cells. Higher levels of IGF‐I have been associated with increased risk of premenopausal breast cancer but not postmenopausal breast ca

Insulin-like growth factor-I, insulin-li
Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and the risk of fibrocystic breast conditions among Chinese women
✍ Chu Chen; Jennifer A. Doherty; S. Kay Lewis; Roberta M. Ray; Dao Li Gao; Helge S 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 94 KB 👁 1 views

## Abstract We investigated whether circulating insulin‐like growth factor‐I (IGF‐I) and insulin‐like growth factor binding protein‐3 (IGFBP‐3) levels are associated with the risk of fibrocystic breast conditions (FBC), in a case‐control study nested within a randomized trial of breast self‐examina